# Horace Mann Educators Corp: financial statements, quarterly

HMN · NYSE · CIK 850141 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hmn.md) · [Financials](/companies/hmn/financials.md) · [Filings](/companies/hmn/filings.md) · [Insiders](/companies/hmn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hmn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [379](/filings/0001628280-24-045020.md) | [403 d](/filings/0000850141-26-000007.md) | [386](/filings/0001628280-25-022718.md) | [388](/filings/0001628280-25-038406.md) | [412](/filings/0000850141-25-000008.md) | [409 d](/filings/0000850141-26-000007.md) | [416](/filings/0000850141-26-000021.md) | [412](/filings/0000850141-26-000033.md) | [439](/filings/0000850141-25-000008.md) | [435 d](/filings/0000850141-26-000007.md) | [429](/filings/0000850141-26-000021.md) | [444](/filings/0000850141-26-000033.md) |
| Interest expense | $m | [7.5](/filings/0001628280-24-045020.md) | [8.6 d](/filings/0000850141-26-000007.md) | [8.7](/filings/0001628280-25-022718.md) | [8.7](/filings/0001628280-25-038406.md) | [8.7](/filings/0000850141-25-000008.md) | [8.5 d](/filings/0000850141-26-000007.md) | [8.9](/filings/0000850141-26-000021.md) | [8.6](/filings/0000850141-26-000033.md) | [8.9](/filings/0000850141-25-000008.md) | [10.0 d](/filings/0000850141-26-000007.md) | [9.5](/filings/0000850141-26-000021.md) | [9.6](/filings/0000850141-26-000033.md) |
| Income tax | $m | [1.9](/filings/0001628280-24-045020.md) | [7.7 d](/filings/0000850141-26-000007.md) | [6.5](/filings/0001628280-25-022718.md) | [0.8](/filings/0001628280-25-038406.md) | [8.4](/filings/0000850141-25-000008.md) | [10.1 d](/filings/0000850141-26-000007.md) | [9.3](/filings/0000850141-26-000021.md) | [7.1](/filings/0000850141-26-000033.md) | [13.2](/filings/0000850141-25-000008.md) | [9.5 d](/filings/0000850141-26-000007.md) | [9.0](/filings/0000850141-26-000021.md) | [7.4](/filings/0000850141-26-000033.md) |
| Net income | $m | [11.7](/filings/0001628280-24-045020.md) | [39.5 d](/filings/0000850141-26-000007.md) | [26.5](/filings/0001628280-25-022718.md) | [3.8](/filings/0001628280-25-038406.md) | [34.3](/filings/0000850141-25-000008.md) | [38.2 d](/filings/0000850141-26-000007.md) | [38.2](/filings/0000850141-26-000021.md) | [29.4](/filings/0000850141-26-000033.md) | [58.3](/filings/0000850141-25-000008.md) | [36.2 d](/filings/0000850141-26-000007.md) | [41.2](/filings/0000850141-26-000021.md) | [41.6](/filings/0000850141-26-000033.md) |
| Diluted EPS | $ per share | [0.28](/filings/0001628280-24-045020.md) | not reported | [0.64](/filings/0001628280-25-022718.md) | [0.09](/filings/0001628280-25-038406.md) | [0.83](/filings/0000850141-25-000008.md) | not reported | [0.92](/filings/0000850141-26-000021.md) | [0.71](/filings/0000850141-26-000033.md) | [1.40](/filings/0000850141-25-000008.md) | not reported | [1.00](/filings/0000850141-26-000021.md) | [1.01](/filings/0000850141-26-000033.md) |
| Basic EPS | $ per share | [0.28](/filings/0001628280-24-045020.md) | not reported | [0.64](/filings/0001628280-25-022718.md) | [0.09](/filings/0001628280-25-038406.md) | [0.83](/filings/0000850141-25-000008.md) | not reported | [0.93](/filings/0000850141-26-000021.md) | [0.71](/filings/0000850141-26-000033.md) | [1.42](/filings/0000850141-25-000008.md) | not reported | [1.01](/filings/0000850141-26-000021.md) | [1.02](/filings/0000850141-26-000033.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.0](/filings/0001628280-23-037309.md) | [0.0](/filings/0000850141-26-000007.md) | [0.0](/filings/0001628280-24-021676.md) | [0.0](/filings/0001628280-24-035671.md) | [0.0](/filings/0001628280-24-045020.md) | [0.0](/filings/0000850141-26-000007.md) | [0.0](/filings/0001628280-25-022718.md) | [0.0](/filings/0001628280-25-038406.md) | [0.0](/filings/0000850141-25-000008.md) | [0.0](/filings/0000850141-26-000033.md) | [0.0](/filings/0000850141-26-000021.md) | [0.0](/filings/0000850141-26-000033.md) |
| Total assets | $bn | [13.4](/filings/0001628280-23-037309.md) | [14.0](/filings/0000850141-26-000007.md) | [14.2](/filings/0001628280-24-021676.md) | [14.3](/filings/0001628280-24-035671.md) | [14.7](/filings/0001628280-24-045020.md) | [14.5](/filings/0000850141-26-000007.md) | [14.4](/filings/0001628280-25-022718.md) | [14.7](/filings/0001628280-25-038406.md) | [15.5](/filings/0000850141-25-000008.md) | [15.3](/filings/0000850141-26-000033.md) | [15.0](/filings/0000850141-26-000021.md) | [15.6](/filings/0000850141-26-000033.md) |
| Total liabilities | $bn | [12.4](/filings/0001628280-23-037309.md) | [12.9](/filings/0001628280-25-008838.md) | [13.0](/filings/0001628280-24-021676.md) | [13.1](/filings/0001628280-24-035671.md) | [13.4](/filings/0001628280-24-045020.md) | [13.2](/filings/0000850141-26-000007.md) | [13.1](/filings/0001628280-25-022718.md) | [13.4](/filings/0001628280-25-038406.md) | [14.0](/filings/0000850141-25-000008.md) | [13.8](/filings/0000850141-26-000033.md) | [13.5](/filings/0000850141-26-000021.md) | [14.1](/filings/0000850141-26-000033.md) |
| Long-term debt | $bn | [0.5](/filings/0001628280-23-037309.md) | [0.5](/filings/0001628280-25-008838.md) | [0.5](/filings/0001628280-24-021676.md) | [0.5](/filings/0001628280-24-035671.md) | [0.5](/filings/0001628280-24-045020.md) | [0.5](/filings/0000850141-26-000007.md) | [0.5](/filings/0001628280-25-022718.md) | [0.5](/filings/0001628280-25-038406.md) | [0.8](/filings/0000850141-25-000008.md) | [0.6](/filings/0000850141-26-000033.md) | [0.6](/filings/0000850141-26-000021.md) | [0.6](/filings/0000850141-26-000033.md) |
| Short-term borrowings | $bn | [0.0](/filings/0001628280-23-037309.md) | [0.0](/filings/0001628280-24-007168.md) | not reported | not reported | not reported | [0.0](/filings/0000850141-26-000007.md) | not reported | not reported | not reported | [0.0](/filings/0000850141-26-000007.md) | not reported | not reported |
| Shareholders' equity | $bn | [1.1](/filings/0001628280-24-045020.md) | [1.2](/filings/0000850141-26-000007.md) | [1.2](/filings/0001628280-25-022718.md) | [1.2](/filings/0001628280-25-038406.md) | [1.3](/filings/0000850141-25-000008.md) | [1.3](/filings/0000850141-26-000007.md) | [1.3](/filings/0000850141-26-000021.md) | [1.4](/filings/0000850141-26-000033.md) | [1.4](/filings/0000850141-25-000008.md) | [1.5](/filings/0000850141-26-000033.md) | [1.5](/filings/0000850141-26-000021.md) | [1.5](/filings/0000850141-26-000033.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [45.3 d](/filings/0001628280-24-045020.md) | [103 d](/filings/0000850141-26-000007.md) | [74.5](/filings/0001628280-25-022718.md) | [40.2 d](/filings/0001628280-25-038406.md) | [144 d](/filings/0000850141-25-000008.md) | [194 d](/filings/0000850141-26-000007.md) | [141](/filings/0000850141-26-000021.md) | [131 d](/filings/0000850141-26-000033.md) | [151 d](/filings/0000850141-25-000008.md) | [130 d](/filings/0000850141-26-000007.md) | [61.3](/filings/0000850141-26-000021.md) | [224 d](/filings/0000850141-26-000033.md) |
| Dividends paid | $m | [13.4 d](/filings/0001628280-24-045020.md) | [13.5 d](/filings/0000850141-26-000007.md) | [13.9](/filings/0001628280-25-022718.md) | [13.9 d](/filings/0001628280-25-038406.md) | [13.9 d](/filings/0000850141-25-000008.md) | [13.8 d](/filings/0000850141-26-000007.md) | [14.3](/filings/0000850141-26-000021.md) | [14.3 d](/filings/0000850141-26-000033.md) | [14.3 d](/filings/0000850141-25-000008.md) | [14.2 d](/filings/0000850141-26-000007.md) | [14.6](/filings/0000850141-26-000021.md) | [14.5 d](/filings/0000850141-26-000033.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.4](/filings/0001628280-24-007168.md) | [41.4](/filings/0001628280-24-021676.md) | [41.4](/filings/0001628280-24-035671.md) | [41.4](/filings/0001628280-24-045020.md) | [41.5](/filings/0001628280-25-022718.md) | [41.6](/filings/0001628280-25-038406.md) | [41.4](/filings/0000850141-25-000008.md) | [41.6](/filings/0000850141-26-000021.md) | [41.6](/filings/0000850141-26-000033.md) | [41.6](/filings/0000850141-25-000008.md) | [41.2](/filings/0000850141-26-000021.md) | [41.2](/filings/0000850141-26-000033.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 40,501,054 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0000850141-26-000033.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.